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Summary.-Radiolabelled affinity-purified antibody to carcinoembryonic antigen
(CEA) was injected i.v. into immune-suppressed mice carrying xenografts of human
breast carcinoma. Its distribution in the tumours was examined by a combination
of immunocytochemistry and autoradiography. The antibody interacted predom-
inantly with the CEA in the extracellular tumour space, rather than on the cell
membrane or cytoplasm.
Since 1973, CEA has been used as a
target for the localization of tumours by
radiolabelled antibody. Initial work in
animal models of human tumours (Primus
et al., 1973; Mach et al., 1974) was followed
by application of this technique in
patients. Thus, Dykes et al. (1980) Golden-
berg et al. (1980) and Mach et al. (1980)
injected 1311-labelled affinity-purified anti-
bodies to CEA in patients, and success-
fully detected CEA-containing primary
and metastatic tumours by external
radio-imaging. However, the site of bind-
ing of the injected anti-CEA antibody to
the tumour CEA has never been demon-
strated at cellular level.
We have recently studied the kinetics
and some of the factors affecting the
localization of anti-CEA antibodies in
human breast tumours growing as xeno-
grafts in immune-suppressed mice (Mosh-
akis et al., 1981a). Having demonstrated
selective homing of antibody in the tum-
ours, a combination of immunocytochem-
istry and autoradiography was used to:
(a) study the distribution of injected
anti-CEA antibodies in the tumour at
histological level; (b) examine whether the
observed in vivo localization was due to
antibody-antigen interaction, and (c) dem-
onstrate the site of this interaction.
MATERIALS AND METHODS
Animal model.-Female CBA/lac mice
(weighing on average 20 g) of the Institute of
Cancer Research were immune-suppressed by
thymectomy and total-body irradiation (6
Gy) preceded by i.p. injection of cytosine
arabinoside (200 mg/kg) (Steel et al., 1978).
An established human breast-carcinoma
xenograft, HX99, was used throughout the
work. Tumours were implanted s.c., bilater-
ally, in the flanks 1-7 days after irradiation.
The tumours have been shown to maintain
their human morphology, human chromo-
some number and histological features (Bailey
et al., 1981). CEA was demonstrated in
conventionally prepared tissue sections, using
a rabbit antiserum (Ormerod, 1978) and an
alkaline phosphatase goat anti-rabbit con-
jugate, as described elsewhere (Bailey et al.,
1982). The content of CEA in this tumour, as
measured after perchloric acid extraction and
radio-immunoassay, was found to be 14-0 +
4 0 ,ug/g (mean of 6 tumours) (Moshakis et al.,
1981a).
Antibody preparation and administration.
-These have been described in detail by
Moshakis et al. (1981a). Briefly, anti-CEA
sera were raised by monthly s.c. injections ofSITE OF ANTI-CEA/TUMOUR CEA INTERACTION Nl'V T() '9
a goat witlh 100 ,ug of CEA purified from
hepatic metastases of a human colonic
carcinoma. The y-globulin fraction of the
immune serum aas affinity purified by pas-
sing it over a column of CEA (15 mg) coval-
ently bound to Sepharose 4B (10 ml). After
waslhing the column wAith 01M PBS, anti-
CEA antibodies wN-ere recovered using 6M
guanidine HCl in 0IM PBS. The reactivity of
the affinity-purified anti-CEA with CEA was
confirmed by immunodiffusion and radio-
immunoassay. The affinity-purified anti-
bodies wNere labelled writh 1251, using
Chloramine T (Greenwood et al., 1963).
Globulin from a non-immunized goat was
labelled by the same method. Typically, an
activity of 1 uCi/,tg wAas attained. Sephacryl
S-300 column chromatography of the radio-
labelled proteins demonstrated the absence
of aggregation and products of degradation.
Two-three weeks after tumour implanta-
tion (range oftumour wreight 28-66 mg; mean
52+4) 15 jug of 1251-labelled anti-CEA or
1251-labelled normal goat globulin wrere
injected i.v. Tumour-bearing animals into
which no protein had been injected were
included in each experiment. All animals
were of the same batch and wN-ere carrying
tumours of the same passage number (13).
Twenty-four to 48 h after injection, mice
Ai-ere exsanguinated and tumours and organs
(salivary gland, thyroid gland, heart, lungs.
liver, spleen, stomach, kidney and intestine)
were removed.
Autoradiography.-When sections w\ere
prepared after fixation in formol saline and
paraffin embedding, it was found that 50-
60% of radiolabelled anti-CEA and 65-75%
of radiolabelled normal goat Ig were lost.
Autoradiography (ARG) therefore, was per-
formed wAith frozen sections as follows:
cryostat sections of tumours and organs were
placed on slides, fixed in formol saline for 5
min only and washed for 5 min in distilled
water. During such fixation, 75-85% of anti-
CEA and normal goat Ig were retained in the
tumour. In pilot experiments. 3 fixatives
N-ere used (formol saline, Bouin's solution and
glutaraldehyde) to establish the solution
(formol saline) wAhich caused the least loss of
radioactivity from tissues and the fewNest
background grains on ARG.
After staining for CEA immunocytochemic-
ally, the slides were then dipped, for 2 sec, in
photographic emulsion (Ilford K5), main-
tained at 50'C and diluted 1:1 Aith distilled
water. After drying the slides for 30 min, they
wrere placed in light-tight boxes containing
silica gel and left at 4°C for periods of 3 days
to 5 weeks. Exposed slides were then devel-
oped (Kodak D19) and fixed (12.5°o Amfix.
Mav & Baker) for 5 min each, and counter-
stained with Mayer's haemalum. Conditions
w-hich gave minimal background activity
without appreciable loss of grain formation
were established in preliminary experiments.
Immunocytochemical staining of slides
was also attempted after the ARGs had been
prepared. However, the emulsion overlay
hindered the development of the immuno-
cytochemical stain.
In addition to the combined ARG/immuno-
cytochemistry slides, each experiment in-
cluded tumour sections with ARG alone and
immunocytochemical staining alone. Each
set of ARGs also included sections which had
not been labelled with antibody in vivo but
had been stained immunocytochemically and
processed as described above.
ARGs were examined both by bright- and
dark-field illumination.
RESULTS
The immunocytochemical stain revealed
that CEA was distributed patchily
throughout the tumour. It was in the cell
cytoplasm, on the cell membrane, in the
necrotic areas and in extracellular spaces
especially in areas of low cell density. On
ARG, grains were seen mainly within the
extracellular spaces. Rarely, grains were
seen around the periphery of a tumour cell.
Within the limits of resolution of the
ARG (which with 125I are poor compared
to 3H), the tumour-cell cytoplasm was
unlabelled. When immunocytochemistry
and ARG were combined on the same
section the extracellular spaces which
showed high concentrations of ARG
grains also stained immunocytochemically
for CEA (see Figure). In contrast there
was minimal grain formation in the
sections containing normal goat Ig, and
the distribution of grains did not correlate
with the location of CEA as shown
immunocytochemically.
In normal tissues, minimal grain forma-
tion with uniform distribution was noted,







FIGURE. Combined autoradiography and
immunocytochemistry of cryostat sections
of the breast-carcinoma xenograft HX99,
labelled in vivo with (a) 125I-anti-CEA and
(b) 125I-normal goat Ig ( x 150). No chemo-
graphy effect by the immunocytochemical
stain was noted in control sections.
both with the radiolabelled anti-CEA and
radio-labelled normal goat Ig. Positive
chemography effects were not produced by
the tissue or the immunocytochemical
stain.
DISCUSSION
Previous studies of the selective uptake
of specific antibodies by tumours have
lacked the final proof that the localization
observed was due to reaction of antibody
with antigen at the site of the tumour.
Our study, combining immunocytochem-
istry and autoradiography, of the uptake
of anti-CEA by a xenografted carcinoma
of human breast, has demonstrated that
the antibody was predominantly in extra-
cellular spaces rich in CEA. The result is
consistent with that of Kim et al. (1980)
who attributed the localization of anti-
AFP in AFP-containing tumours to the
"extracellular milieu" of AFP in the
tumour, thoughtheir claim was not proved
histologically.
The specific antibodies react with se-
creted CEA molecules collected in the
extracellular spaces. The antibody reaches
the tumour via the blood pool, which also
contains secreted CEA. In our previous
study (Moshakis et al., 1981a) we measured
the formation and clearance of immune
complexes from the blood. Despite the
presence of such complexes, free Ig was
always in excess. Furthermore, the degree
of localization of specific antibody de-
pended on the amount of CEA stored in
the tumour; the level of circulating CEA
was unimportant. Presumably higher
levels of immune complexes are formed in
the tumourbecause the local concentration
of CEA is higher at that site.
The paucity oflabelled antibody on cell
membranes could be due either to the
inaccessibility of antibody to many of the
cell surfaces, or to the lability of the com-
plexes formed. Rosenthal et al. (1980)
have shown that CEA anti-CEA com-
plexes are removed from the surface of
cultured colon carcinoma cells by endo-
cytosis. Once inside the cell, the antigen
antibody complexes would probably be
degraded.
Inaccessibility of antibodies to cell
surfaces could also explain the lack of
studies describing tumour cytotoxicity in
vivo by anti-CEA, either alone or con-
jugated to therapeutic agents. In our
experience, anti-CEA ricin conjugates did
not cause a worthwhile or persistent
cytotoxic effect in vivo in the xenografted
tumour (HX 99) used in this study
(Thorpe et al., work in progress). Localiza-
tion of antibody toxin conjugates in
extracellular spaces would be unlikely to
give selective cytotoxicity.
It must be emphasized that CEA is only
one of several membrane componentsSITE OF ANTI-CEA/TUMOUR CEA INTERACTION IN VIVO 21
which might be potential target antigens
for tumour localization or therapy The
specific localization obtained with anti-
CEA is not particularly good. Greatly
improved indices of localization have been
obtained recently in some other tumours,
using newly developed monoclonal anti-
bodies to tumour-cell surfaces (Moshakis
etal., 1981b, c; Ballou et al., 1979; Houston
et al., 1980). This paper underlines the
value of undertaking autoradiographic
studies before embarking on targeted
drug therapy.
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